Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
STAMFORD, Conn., May 12, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a key opinion leader (KOL) breakfast meeting focused on CR845’s potential to treat patients with chronic kidney disease (CKD)-associated pruritus on Tuesday, May 16, 2017 from 8:30 to 10:30 a.m. ET in New York.
The meeting will feature keynote presentations from Steven Zeig, M.D., Nephrologist and Principal Investigator, Pines Clinical Research Inc., and Shayan Shirazian, M.D., Nephrologist and Clinical Researcher, Winthrop-University Hospital and Stony Brook University School of Medicine. Additionally, executives from Cara will review the data from Part A of the Phase 2/3 trial in patients with CKD-associated pruritus and provide an overview of the CR845 program.
A live audio webcast of the event and accompanying slides can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara Therapeutics is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
